Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled …
RL Coleman, AM Oza, D Lorusso, C Aghajanian… - The Lancet, 2017 - thelancet.com
Background Rucaparib, a poly (ADP-ribose) polymerase inhibitor, has anticancer activity in
recurrent ovarian carcinoma harbouring a BRCA mutation or high percentage of genome …
recurrent ovarian carcinoma harbouring a BRCA mutation or high percentage of genome …
Sporadic epithelial ovarian cancer: clinical relevance of BRCA1 inhibition in the DNA damage and repair pathway
JI Weberpals, KV Clark-Knowles… - Journal of Clinical …, 2008 - ascopubs.org
Among the most promising pathways for molecular targets in sporadic epithelial ovarian
cancer (SEOC) are those involving the BRCA1 protein. Because somatic mutations in …
cancer (SEOC) are those involving the BRCA1 protein. Because somatic mutations in …
Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial
Summary Background The Wee1 (WEE1hu) inhibitor adavosertib and gemcitabine have
shown preclinical synergy and promising activity in early phase clinical trials. We aimed to …
shown preclinical synergy and promising activity in early phase clinical trials. We aimed to …
Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised …
JA Ledermann, AM Oza, D Lorusso… - The Lancet …, 2020 - thelancet.com
Background In ARIEL3, rucaparib maintenance treatment significantly improved progression-
free survival versus placebo. Here, we report prespecified, investigator-assessed …
free survival versus placebo. Here, we report prespecified, investigator-assessed …
Targeting genetic and epigenetic alterations in the treatment of serous ovarian cancer
Genomic information is being used to develop robust prognostic and predictive biomarkers
that will provide companion diagnostics for emerging molecular targeted therapies. The …
that will provide companion diagnostics for emerging molecular targeted therapies. The …
A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive TP53-mutant Ovarian …
Purpose: Preclinical studies show that adavosertib, a WEE1 kinase inhibitor, sensitizes
TP53-mutant cells to chemotherapy. We hypothesized that adavosertib, plus chemotherapy …
TP53-mutant cells to chemotherapy. We hypothesized that adavosertib, plus chemotherapy …
A phase II study of single-agent RO4929097, a gamma-secretase inhibitor of Notch signaling, in patients with recurrent platinum-resistant epithelial ovarian cancer: A …
I Diaz-Padilla, MK Wilson, BA Clarke, HW Hirte… - Gynecologic …, 2015 - Elsevier
Purpose A phase II study was performed to evaluate the efficacy and safety of single-agent
RO4929097 (a gamma-secretase inhibitor) in patients with recurrent platinum-resistant …
RO4929097 (a gamma-secretase inhibitor) in patients with recurrent platinum-resistant …
[HTML][HTML] Patient-centered outcomes in ARIEL3, a phase III, randomized, placebo-controlled trial of rucaparib maintenance treatment in patients with recurrent ovarian …
AM Oza, D Lorusso, C Aghajanian… - Journal of Clinical …, 2020 - ncbi.nlm.nih.gov
Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of
Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma - PMC Back …
Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma - PMC Back …
Vulvar squamous cell carcinoma (VSCC) as two diseases: HPV status identifies distinct mutational profiles including oncogenic fibroblast growth factor receptor 3
JI Weberpals, B Lo, MM Duciaume, JN Spaans… - Clinical Cancer …, 2017 - AACR
Purpose: Patients with advanced or recurrent invasive vulvar squamous cell carcinoma
(VSCC) have limited treatment options and a grave prognosis. Understanding the genomic …
(VSCC) have limited treatment options and a grave prognosis. Understanding the genomic …
[HTML][HTML] Retrospective analysis of Schlafen11 (SLFN11) to predict the outcomes to therapies affecting the DNA damage response
SE Willis, C Winkler, MP Roudier, T Baird… - British Journal of …, 2021 - nature.com
Background The absence of the putative DNA/RNA helicase Schlafen11 (SLFN11) is
thought to cause resistance to DNA-damaging agents (DDAs) and PARP inhibitors. Methods …
thought to cause resistance to DNA-damaging agents (DDAs) and PARP inhibitors. Methods …